ReviewMolecular biology reports2026
Role of PRDM1 in natural killer cells.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PRDM1, a pivotal transcription factor within the PRDM family, serves as a critical regulator of Natural Killer (NK) cell biology. Initially identified as PRDⅠ-BF1/BLIMP-1, PRDM1 is characterized by a conserved PR domain and multiple zinc finger motifs, which enable its sequence-specific DNA binding and protein-protein interactions. Its expression in NK cells is tightly regulated by upstream transcription factors as well as cytokine signaling. Mechanistically, PRDM1 exerts transcriptional repression through several coordinated mechanisms: direct DNA binding to target gene promoters, induction of chromatin remodeling via histone modification, and recruitment of co-repressors like Groucho and histone deacetylases, thereby orchestrating NK cell maturation and effector functions. These direct molecular functions of PRDM1 have been characterized largely in vitro. In vivo, PRDM1 also shapes NK cell maturation and effector functions; however, phenotypes observed in knockout mice reflect the integrated outcome of PRDM1 loss throughout NK cell development, differentiation and homeostasis, in which compensatory mechanisms may operate, and therefore cannot be attributed solely to the direct cell-intrinsic functions of PRDM1. This review synthesizes the historical evolution of PRDM1 research, elucidates its structural characteristics, and details its gene regulatory mechanisms. A comprehensive understanding of the PRDM1 regulatory network offers profound insights into NK cell biology and highlights potential therapeutic targets for immune-related disorders such as autoimmune diseases and cancer immunotherapy.
Indexed as
Identifiers
42878988What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.